NCT00056381已完成1 期
Phase I/II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Fever and Neutropenia
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 25
- 试验地点
- 2
研究概览
简要总结
Anidulafungin is a medicine being developed for treatment of adults with certain kinds of fungal infections. This study is evaluating anidulafungin in children and adolescents who have fever and a low white blood cell count (neutropenia).
详细描述
Anidulafungin is an investigational drug being developed as an intravenous treatment for esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and other filamentous fungi.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive CandidiasisCandidiasisNCT00056368Pfizer256
已完成
2 期
The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)CandidiasisNCT00041704Pfizer19
已完成
1 期
Anidulafungin in Treating Immunocompromised Children With NeutropeniaInfectionNeutropeniaUnspecified Childhood Solid Tumor, Protocol SpecificNCT00068471National Cancer Institute (NCI)
已完成
3 期
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive CandidiasisCandidemiaNCT00761267Pfizer70
已完成
2 期
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.CandidiasisNCT00037219Pfizer120